within Pharmacolibrary.Drugs.ATC.V;

model V04CK02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003,
    adminDuration  = 600,
    adminMass      = 0.02 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V04CK02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pancreozymin, also known as cholecystokinin (CCK), is a peptide hormone that stimulates the digestion of fat and protein by stimulating the gallbladder to contract and pancreas to secrete digestive enzymes. Historically, synthetic CCK was used diagnostically to test gallbladder function or stimulate pancreatic enzyme output in clinical settings; however, it is not used therapeutically or as a mainstream diagnostic drug today, and is not approved for general use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were estimated using available biological and molecular characteristics, as published PK studies of synthetic cholecystokinin in humans do not exist or are not indexed in the primary pharmacokinetic literature. Estimates are for healthy adult individuals after intravenous bolus.</p><h4>References</h4><ol><li><p>Unger, RH, &amp; Eisentraut, AM (1969). Entero-insular axis. <i>Archives of internal medicine</i> 123(3) 261–266. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4885674/\">https://pubmed.ncbi.nlm.nih.gov/4885674</a></p></li><li><p>Webber, C, et al., &amp; Rovati, LC (2003). Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 33(6) 625–641. DOI:<a href=\"https://doi.org/10.1080/0049825031000089137\">10.1080/0049825031000089137</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12851039/\">https://pubmed.ncbi.nlm.nih.gov/12851039</a></p></li><li><p>Viering, O, et al., &amp; Pfob, CH (2024). Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer. <i>Clinical nuclear medicine</i> 49(12) 1091–1097. DOI:<a href=\"https://doi.org/10.1097/RLU.0000000000005355\">10.1097/RLU.0000000000005355</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39093043/\">https://pubmed.ncbi.nlm.nih.gov/39093043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V04CK02;
